

SOLICITOR

OCT 22 2007

AO 120 (Rev. 3/04)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	U.S. PATENT & TRADEMARK OFFICE REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
filed in the U.S. District Court TRENTON, NJ on the following ☒ Patents or ☐ Trademarks:

DOCKET NO. 07-CV-5001 (FLW)	DATE FILED 10/17/2007	U.S. DISTRICT COURT TRENTON, NJ
PLAINTIFF SEPRACOR INC. UNIVERSITY OF MASSACHUSETTS		DEFENDANT DR. REDDY'S LABORATORIES, LTD. DR. REDDY'S LABORATORIES, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 7,214,683		SEE ATTACHED COMPLAINT
2 7,214,684		
3		
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK <i>William J. Walsh/CE</i>	(BY) DEPUTY CLERK <i>Charmaine Ellington</i>	DATE 10/18/2007
-------------------------------------	---	--------------------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

LOCAL CIVIL RULE 11.2 & 40.1 CERTIFICATION

I hereby certify that the matters captioned: (1) *Schering Corporation v. Zydus Pharmaceuticals, USA, Inc., et al.*, Civil Action No. 06-4715 (MLC) (D.N.J.); (2) *Schering Corporation v. Caraco Pharmaceutical Laboratories Ltd., et al.*, Civil Action No. 06-14386 (E.D. Mich.); and (3) *Schering Corporation v. GeoPharma Inc., et al.*, Civil Action No. 06-1843 (M.D. Fla.), which have been consolidated before the Honorable Mary L. Cooper under the caption, *In Re: Desloratadine Patent Litigation*, MDL No. 1851 (MLC) (D.N.J.), are related patent infringement cases because the defendants in the matter in controversy are defendants in the previously identified matter, and the alleged acts causing the infringement in both cases are the same, *i.e.*, based upon the defendants' filing of the same ANDAs with the FDA. Also, the patents asserted in the current matter are related to the previously identified matter because all the patents are associated with Clarinex® products.

I also certify that the matter captioned, *Sepracor Inc., et al. v. Orchid Chemicals & Pharmaceuticals Ltd., et al.*, Civil Action No. 07-4623 (MLC) (D.N.J.), assigned to Judge Cooper, is a related action because it involves the same plaintiffs and two of the same patents as the matter in controversy.

I also certify that the matters captioned, *Sepracor Inc., et al. v. Glenmark Pharmaceuticals, Ltd., et al.*, Civil Action No. 07-3385 (SRC) (D.N.J.) and *Sepracor Inc., et al. v. Sun Pharmaceutical Industries Ltd., et al.*, Civil Action No. 07-4213 (JAP) (D.N.J.), are related actions because they involve the same plaintiffs and two of the same patents as the matter in controversy.

In light of the number of related cases pending before different judges, I submitted a letter to the Honorable Garrett E. Brown, Chief Judge of this Court, on September 19, 2007, to

request that the related cases, including the current matter, be reassigned to Judge Cooper, before whom the earlier filed, related cases are pending. As stated in my letter, reassigning these cases will avoid a situation where many different judges could be separately presiding over each one of the several related cases, in turn, impacting judicial resources and possibly resulting in inconsistent rulings.

I further certify that, to the best of my knowledge, the matter in controversy is not the subject of any other action pending in any court, or of any pending arbitration or administrative proceeding.

Dated: October 17, 2007

By: s/ Charles M. Lizza
Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza
Newark, New Jersey 07102-5490
(973) 286-6700
clizza@saul.com

*Attorneys for Plaintiffs
Sepracor Inc. and
University of Massachusetts*

OF COUNSEL:

Dominick A. Conde
William E. Solander
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, New York 10112
(212) 218-2100
dconde@fchs.com

Charles M. Lizza
William C. Baton
Saul Ewing LLP
One Riverfront Plaza
Newark, New Jersey 07102-5490
Telephone: (973) 286-6700
clizza@saul.com

*Attorneys for Plaintiffs
Sepracor Inc. and
University of Massachusetts*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

<hr/>)	
SEPRACOR INC. and UNIVERSITY)	
OF MASSACHUSETTS,)	Civil Action No.:
)	
Plaintiffs,)	
)	
v.)	COMPLAINT FOR PATENT
)	INFRINGEMENT
DR. REDDY'S LABORATORIES, LTD.)	
and DR. REDDY'S LABORATORIES,)	
INC.,)	(Filed Electronically)
)	
Defendants.)	
<hr/>)	

Plaintiffs Sepracor Inc. ("Sepracor") and University of Massachusetts ("UMass"),
by their attorneys, for their Complaint against Defendants Dr. Reddy's Laboratories, Ltd.
("DRLL") and Dr. Reddy's Laboratories, Inc. ("DRLI"), hereby allege as follows:

Nature of the Action

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. § 100 *et seq.*, arising from Defendants' filing of an Abbreviated New Drug Application ("ANDA") with the United States Food and Drug Administration ("FDA") seeking approval to commercially market a generic version of the patented Clarinex[®] drug products prior

to the expiration of United States Patent No. 7,214,683 ("the '683 patent") and United States Patent No. 7,214,684 ("the '684 patent"), which are owned by Sepracor and UMass.

The Parties

2. Plaintiff Sepracor is a corporation organized and existing under the laws of the State of Delaware, having a place of business at 84 Waterford Drive, Marlborough, Massachusetts 01752.

3. Plaintiff UMass is a public institution of higher education of the Commonwealth of Massachusetts, having a place of business at 55 Lake Avenue North, Worcester, Massachusetts 01655.

4. Upon information and belief, Defendant DRLI is a New Jersey corporation and a wholly owned subsidiary, agent and/or alter-ego of DRLL having a place of business at 200 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807.

5. Upon information and belief, Defendant DRLL is an Indian corporation having a place of business at 7-1-27 Ameerpet, Hyderabad 500 016, Andhra Pradesh, India. Upon information and belief, Defendant DRLL manufactures numerous generic drugs for sale and use throughout the United States, including in this judicial district, through its wholly owned subsidiary, agent and/or alter-ego Defendant DRLI, which is located at 200 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807, as its agent in New Jersey for the receipt of any service of process in this action.

6. DRLL and DRLI are hereinafter collectively referred to as "DRL."

Jurisdiction and Venue

7. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

8. This Court has personal jurisdiction over DRLL and DRLI by virtue of the fact that, *inter alia*, each has committed, or aided, abetted, contributed to and/or participated in the commission of, an act of patent infringement. This Court has personal jurisdiction over each for the additional reasons set forth below (and paragraphs 4 and 5 above) and for other reasons that will be presented to the Court if jurisdiction is challenged.

9. This Court has personal jurisdiction over Defendant DRLI by virtue of the fact that, *inter alia*, DRLI is a New Jersey corporation.

10. This Court has personal jurisdiction over Defendant DRLL by virtue of, *inter alia*: (1) its presence in New Jersey, including through its subsidiary, agent and/or alter ego DRLI; and (2) its systematic and continuous contacts with New Jersey, including through its subsidiary, agent and/or alter ego DRLI.

11. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

The Patents In Suit and the Clarinex® Drug Products

12. On May 8, 2007, the '683 patent, entitled "Compositions of Descarboethoxyloratadine," was duly and legally issued. Sepracor and UMass are assignees of the entire right, title and interest in the '683 patent. A copy of the '683 patent is attached hereto as Exhibit A.

13. On May 8, 2007, the '684 patent, entitled "Methods for the Treatment of Allergic Rhinitis," was duly and legally issued. Sepracor and UMass are assignees of the entire right, title and interest in the '684 patent. A copy of the '684 patent is attached hereto as Exhibit B.

14. The '683 and '684 patents are identified in the FDA publication entitled "Approved Drug Products with Therapeutic Equivalence Evaluations" in association with extended release tablets containing desloratadine and pseudoephedrine sulfate, which are sold as a commercial product under the trade name Clarinex[®], and those patents cover an approved use of commercial Clarinex[®].

Acts Giving Rise to this Action

15. Plaintiff Sepracor received a letter from DRL, dated September 4, 2007 ("the Notification Letter"), notifying them that Defendants had filed with the FDA an ANDA (No. 79-027) under § 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)) to obtain FDA approval to engage in the commercial manufacture, importation, use, offer for sale or sale of extended release tablets containing 2.5 mg desloratadine and 120 mg pseudoephedrine sulfate ("DRL's Proposed Products").

16. Upon information and belief, Defendants intend to engage and will engage in the commercial manufacture, importation, use, offer for sale or sale of DRL's Proposed Products promptly upon receiving FDA approval to do so.

17. The Notification Letter states that ANDA No. 79-027 contains a "Paragraph IV Certification" that, in Defendants' opinion, the '683 and '684 patents are invalid.

18. The Notification Letter does not allege that the '683 and '684 patents are unenforceable, or that the marketing of DRL's Proposed Products will not infringe claims of the '683 or the '684 patent.

Count I – Infringement of the ‘683 Patent by Defendants

19. Plaintiffs repeat and reallege the allegations of paragraphs 1-18 as though fully set forth herein.

20. Defendants’ submission of its ANDA to obtain approval to engage in the commercial manufacture, importation, use, offer for sale or sale of DRL’s Proposed Products, prior to the expiration of the ‘683 patent, constitutes infringement of one or more of the claims of the ‘683 patent under 35 U.S.C. § 271(e)(2)(A).

21. Unless enjoined by this Court, upon FDA approval of ANDA No. 79-027, DRL will infringe the ‘683 patent under 35 U.S.C. § 271 by making, using, importing, offering to sell, or selling DRL’s Proposed Products in the United States.

22. Defendants had notice of the ‘683 patent prior to undertaking their acts of infringement. Defendants’ certification to the FDA that its proposed product will not infringe and/or that the ‘683 patent is invalid or unenforceable lacked a good faith basis. Defendants’ filing of its ANDA constitutes a wholly unjustified infringement of the ‘683 patent, and makes this action exceptional under 35 U.S.C. § 285.

23. Plaintiffs will be substantially harmed if DRL’s infringement of the ‘683 patent is not enjoined, and Plaintiffs are entitled to equitable relief.

Count II – Infringement of the ‘684 Patent by Defendants

24. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set forth herein.

25. Defendants’ submission of its ANDA to obtain approval to engage in the commercial manufacture, importation, use, offer for sale or sale of DRL’s Proposed Products,

prior to the expiration of the '684 patent, constitutes infringement of one or more of the claims of the '684 patent under 35 U.S.C. § 271(e)(2)(A).

26. Unless enjoined by this Court, upon FDA approval of ANDA No. 79-027, DRL will infringe the '684 patent under 35 U.S.C. § 271 by making, using, importing, offering to sell, or selling DRL's Proposed Products in the United States.

27. Defendants had notice of the '684 patent prior to undertaking their acts of infringement. Defendants' certification to the FDA that its proposed product will not infringe and/or that the '684 patent is invalid or unenforceable lacked a good faith basis. Defendants' filing of its ANDA constitutes a wholly unjustified infringement of the '684 patent, and makes this action exceptional under 35 U.S.C. § 285.

28. Plaintiffs will be substantially harmed if DRL's infringement of the '684 patent is not enjoined, and Plaintiffs are entitled to equitable relief.

Prayer for Relief

WHEREFORE, Plaintiffs respectfully request the following relief:

A. A Judgment declaring that Defendants have infringed one or more claims of the '683 patent;

B. A Judgment declaring that Defendants have infringed one or more claims of the '684 patent;

C. An Order that the effective date of any FDA approval of Defendants' ANDA No. 79-027 be no earlier than the date on which the '683 patent expires, including any regulatory or patent term extension;

D. An Order that the effective date of any FDA approval of Defendants' ANDA No. 79-027 be no earlier than the date on which the '684 patent expires, including any regulatory or patent term extension;

E. Preliminary and permanent injunctions enjoining Defendants and their officers, agents, attorneys and employees, and those acting in privity or concert with them, from making, using, importing, offering to sell, or selling DRL's Proposed Products until after the expiration of the '683 patent, including any regulatory or patent term extension;

F. Preliminary and permanent injunctions enjoining Defendants and their officers, agents, attorneys and employees, and those acting in privity or concert with them, from making, using, importing, offering to sell, or selling DRL's Proposed Products until after the expiration of the '684 patent, including any regulatory or patent term extension;

G. A declaration that the commercial manufacture, use, importation into the United States, sale or offering for sale of DRL's Proposed Products will directly infringe or induce and/or contribute to infringement of the '683 patent;

H. A declaration that the commercial manufacture, use, importation into the United States, sale or offering for sale of Defendants's Proposed Products will directly infringe or induce and/or contribute to infringement of the '684 patent;

I. If Defendants engage in the commercial manufacture, use, importation into the United States, offer to sell, or sale of DRL's Proposed Products prior to the expiration of the '683 patent, a Judgment awarding damages to Plaintiffs resulting from such infringement, increased to treble the amount found or assessed based on the willfulness of the infringement, together with interest;

J. If Defendants engage in the commercial manufacture, use, importation into the United States, offer to sell, or sale of DRL's Proposed Products prior to the expiration of the '684 patent, a Judgment awarding damages to Plaintiffs resulting from such infringement, increased to treble the amount found or assessed based on the willfulness of the infringement, together with interest;

K. Attorneys fees in this action based on willful infringement pursuant to 35 U.S.C. § 284 and/or as an exceptional case pursuant to 35 U.S.C. §§ 271 and 285;

L. Costs and expenses in this action; and

M. Such further and other relief as this Court may deem just and proper.

Dated: October 17, 2007

Respectfully submitted,

s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
Saul Ewing LLP
One Riverfront Plaza
Newark, New Jersey 07102-5490
(973) 286-6700
clizza@saule.com

*Attorneys for Plaintiffs
Sepracor Inc. and
University of Massachusetts*

OF COUNSEL:

Dominick A. Conde
William E. Solander
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, New York 10112
(212) 218-2100
dconde@fchs.com